TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06786533: Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

Sponsor: Hemogenyx Pharmaceuticals LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06786533 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06786533 Rescue Dossier →